CN117343875A - 一株格氏乳杆菌my5及其在制备抗炎和通便护肠食品药品中的应用 - Google Patents
一株格氏乳杆菌my5及其在制备抗炎和通便护肠食品药品中的应用 Download PDFInfo
- Publication number
- CN117343875A CN117343875A CN202311316085.XA CN202311316085A CN117343875A CN 117343875 A CN117343875 A CN 117343875A CN 202311316085 A CN202311316085 A CN 202311316085A CN 117343875 A CN117343875 A CN 117343875A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus gasseri
- strain
- probiotic
- activity
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000186606 Lactobacillus gasseri Species 0.000 title claims abstract description 114
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 235000013305 food Nutrition 0.000 title abstract description 9
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 8
- 239000003814 drug Substances 0.000 title abstract description 6
- 239000008141 laxative Substances 0.000 title abstract description 4
- 230000002475 laxative effect Effects 0.000 title abstract description 4
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000006041 probiotic Substances 0.000 claims abstract description 34
- 235000018291 probiotics Nutrition 0.000 claims abstract description 34
- 230000000529 probiotic effect Effects 0.000 claims abstract description 32
- 108010059892 Cellulase Proteins 0.000 claims abstract description 12
- 229940106157 cellulase Drugs 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000000813 microbial effect Effects 0.000 claims description 7
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 6
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 6
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 5
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 5
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 40
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract description 14
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract description 14
- 229940022698 acetylcholinesterase Drugs 0.000 abstract description 14
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 13
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 13
- 239000001913 cellulose Substances 0.000 abstract description 11
- 229920002678 cellulose Polymers 0.000 abstract description 11
- 230000000968 intestinal effect Effects 0.000 abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 9
- 238000010521 absorption reaction Methods 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008103 glucose Substances 0.000 abstract description 9
- 230000001603 reducing effect Effects 0.000 abstract description 8
- 206010010774 Constipation Diseases 0.000 abstract description 6
- 230000002550 fecal effect Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 210000000936 intestine Anatomy 0.000 abstract description 4
- 230000008855 peristalsis Effects 0.000 abstract description 3
- 230000002040 relaxant effect Effects 0.000 abstract description 3
- 230000031891 intestinal absorption Effects 0.000 abstract description 2
- 238000000855 fermentation Methods 0.000 description 17
- 230000004151 fermentation Effects 0.000 description 17
- 239000002609 medium Substances 0.000 description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000005526 G1 to G0 transition Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 101001076687 Lactobacillus gasseri Inulosucrase Proteins 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940099596 manganese sulfate Drugs 0.000 description 4
- 239000011702 manganese sulphate Substances 0.000 description 4
- 235000007079 manganese sulphate Nutrition 0.000 description 4
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 239000002068 microbial inoculum Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 3
- 239000001393 triammonium citrate Substances 0.000 description 3
- 235000011046 triammonium citrate Nutrition 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100039019 Nuclear receptor subfamily 0 group B member 1 Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013272 agar well diffusion method Methods 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 239000002361 compost Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920003168 pharmaceutical polymer Polymers 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/42—Hydroxy-carboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
Abstract
本发明属于益生菌及其应用技术领域,具体涉及一株格氏乳杆菌MY5及其在制备抗炎和通便护肠食品药品中的应用。为进一步开发利用格氏乳杆菌的益生功能,本发明从中国广东地区一名健康成年人的粪便样品中分离纯化得到一株格氏乳杆菌(Lactobacillus gasseri)MY5菌株,该菌株具有的多种益生功效,包括具有优越的纤维素酶活性,可产生和分泌3‑羟基丁酸,可抑制α‑葡萄糖苷酶活性,可抑制乙酰胆碱酯酶活性。因此,MY5菌株具有促进对纤维素的吸收,改善便秘;可抗炎和改善肠道菌群;降糖;促进肠道吸收和蠕动等多种功能,可用于抗炎和通便护肠等领域,具有重要的应用价值和经济价值。
Description
技术领域
本发明属于益生菌及其应用技术领域,具体涉及一株格氏乳杆菌MY5及其在制备抗炎和通便护肠食品药品中的应用。
背景技术
格氏乳杆菌(Lactobacillus gasseri),又称为加氏乳杆菌,是一种厌氧的革兰氏阳性细菌,属于乳酸菌的范畴,天然存在于胃肠道、阴道或母乳中。格氏乳杆菌能够在酸性环境中存活和繁殖,这使得它能够在食品和胃酸的环境下存活。格氏乳杆菌是乳酸菌属的一员,能够通过发酵转化碳水化合物为乳酸,从而降低环境pH值。此外,格氏乳杆菌具有良好的耐酸和耐胆盐特性,能在人和动物的肠胃中生存。
格氏乳杆菌被美国FDA定义为一般公认安全类添加剂(GRAS)状态的微生物,是可用于食品的益生菌菌种之一。格氏乳杆菌广泛地存在于人和动物的肠道,并随粪便排出。格氏乳杆菌是人体正常菌群的一部分,其作为肠道正常微生物体系的重要组成,并终生伴随宿主,对维持肠道微生态平衡有重要意义。近年来,格氏乳杆菌作为一种具有极大潜力的益生性乳杆菌已成为近年研究的热点,并且正在不断被用来制作成适用于人和动物的益生菌制剂。
研究表明,不同的格氏乳杆菌菌株具有不同的益生功能。比如:(1)格氏乳杆菌TF08-1菌株能调节脂代谢,可以降低血脂,降低动脉粥样硬化相关疾病、心血管疾病的相关指标,并能够显著降低血液粘度,从而有效地防止血液处于高黏、高凝状态,改善血液流变学,改善血管病变;减轻肝脏负担,减少脂质代谢紊乱,从而预防脂肪肝的形成。(2)格氏乳杆菌LG08可以分解大部分尿酸合成的前体物质,减少尿酸的合成;还可以分解肠道中的尿酸,并通过降低血清内毒素水平及抑制黄嘌呤氧化酶的活性,进一步抑制尿酸的生成并缓解炎症等副反应。因此,格氏乳杆菌具有分解嘌呤的能力与抑制黄嘌呤活性的能力。(3)格氏乳杆菌G098可以通过减少结肠组织的粘膜损伤、调节免疫反应、恢复肠道菌群多样性和增加肠道菌群稳定性等途径来缓解DSS引起的小鼠结肠炎。(4)格氏乳杆菌对人体有益,它在肠道内起着重要的生态平衡和保护作用。它能够通过产生乳酸和其他有益物质,调节肠道的酸碱度,抑制有害菌的生长,维持肠道的正常菌群结构。格氏乳杆菌还有助于增强免疫系统功能,改善消化和吸收,促进营养物质的代谢,预防腹泻和便秘等肠道问题。
由于格氏乳杆菌具有来源多样性,导致其具有基因多样性和功能多样性。然而,目前针对格氏乳杆菌的分离鉴定、益生特性和代谢机制的研究依然较少,这在一定程度上也影响了对格氏乳杆菌的开发利用。因此,有必要根据格氏乳杆菌的不同来源挖掘不同的益生功能,使其更好地发挥作用,如根据菌株的功能或者益生代谢产物确定其功效,明确其应用前景。综上所述,益生性格氏乳杆菌的研究及应用有很广阔的发展空间。
发明内容
为了克服上述现有技术的不足,本发明从中国广东地区一名健康成年人的粪便样品中分离纯化得到一株格氏乳杆菌(Lactobacillus gasseri)MY5菌株,该菌株具有优越的纤维素酶活性,可抑制乙酰胆碱酯酶活性等多种功能,具有重要的潜在应用价值。
为了实现上述目的,本发明所采用的技术方案是:
本发明第一方面提供了一株格氏乳杆菌(Lactobacillus gasseri)MY5菌株,所述格氏乳杆菌MY5菌株于2023年7月3日保藏于中国典型培养物保藏中心,保藏号为:CCTCCNO:M 20231160;所述格氏乳杆菌MY5菌株的16S rDNA全序列如SEQ ID No:1所示。
本发明第二方面提供了第一方面所述的格氏乳杆菌(Lactobacillus gasseri)MY5菌株在产纤维素酶中的应用。
经研究发现,益生菌格氏乳杆菌MY5菌株可产纤维素酶,提示格氏乳杆菌MY5菌株可用于生产纤维素酶,并通过产纤维素酶这一特性用于促进人体对食物中蛋白质的消化吸收,提高对小肽和氨基酸的吸收,抗过敏等领域。
本发明第三方面提供了第一方面所述的格氏乳杆菌(Lactobacillus gasseri)MY5菌株在产3-羟基丁酸中的应用。
经研究发现,益生菌格氏乳杆菌MY5菌株可产3-羟基丁酸(3-HB),提示格氏乳杆菌MY5菌株可用于生产3-HB,并通过产3-HB这一特性用于为身体各种活动提供能量,抗骨质疏松,预防及治疗慢性综合征,改善脑部认知功能,改善脂代谢等领域。
本发明第四方面提供了第一方面所述的格氏乳杆菌(Lactobacillus gasseri)MY5菌株在制备α-葡萄糖苷酶抑制剂中的应用。
经研究发现,益生菌格氏乳杆菌MY5菌株可有效抑制α-葡萄糖苷酶活性,而α-葡萄糖苷酶与2型糖尿病有关,抑制α-葡萄糖苷酶是控制餐后高血糖的方法之一,提示格氏乳杆菌MY5菌株有望用于降血糖和抑制肥胖等领域。
本发明第五方面提供了第一方面所述的格氏乳杆菌(Lactobacillus gasseri)MY5菌株在制备乙酰胆碱酯酶抑制剂中的应用。
经研究发现,益生菌格氏乳杆菌MY5菌株可有效抑制乙酰胆碱酯酶活性,提示格氏乳杆菌MY5菌株可通过抑制乙酰胆碱酯酶活性用于增强认知能力和记忆力,扩张血管,兴奋骨骼肌和平滑肌等领域。
本发明第六方面提供了一种具有益生功能的菌剂,其特征在于,所述菌剂包括第一方面所述的格氏乳杆菌(Lactobacillus gasseri)MY5菌株。
优选地,所述菌剂为第一方面所述的格氏乳杆菌(Lactobacillus gasseri)MY5菌株经发酵后的产物。
优选地,在医药应用领域,所述菌剂还包括药学上可接受的辅料。
更优选地,所述辅料包括载体和赋形剂。所述赋形剂是指可用于药学领域的稀释剂、黏合剂、润滑剂、崩解剂、助溶剂、稳定剂等以及一些药用基质。所述载体是药物领域中可得到的功能性药用辅料,包括表面活性剂、助悬剂、乳化剂以及一些新型药用高分子材料,如环糊精、壳聚糖、聚乳酸(PLA)、聚乙醇酸聚乳酸共聚物(PLGA)、透明质酸等。
优选地,在医药应用领域,所述菌剂的剂型包括片剂、颗粒剂、胶囊剂、滴丸剂、缓释剂、口服液制剂、注射剂。
更优选地,上述剂型是指临床上常用的剂型。药物制剂可以经口服或胃肠外方式(例如静脉、皮下、腹膜内或局部)给药,如果某些药物在胃部条件下是不稳定的,可将其制备成肠衣片剂。
与现有技术相比,本发明的有益效果是:
本发明从中国广东地区一名健康成年人的粪便样品中分离纯化得到一株格氏乳杆菌(Lactobacillus gasseri)MY5菌株,菌株MY5具有的多种益生功效,包括具有优越的纤维素酶活性,可产生和分泌3-羟基丁酸,可抑制α-葡萄糖苷酶活性,可抑制乙酰胆碱酯酶活性。因此,格氏乳杆菌MY5菌株具有促进对纤维素的吸收,改善便秘;可抗炎和改善肠道菌群;降糖;促进肠道吸收和蠕动等多种功能。可见,本发明新分离得到的格氏乳杆菌MY5菌株具有多种益生功效,可用于抗炎和通便护肠等领域,比如,制作成抗炎和通便护肠药品,具有重要的应用价值和经济价值。
附图说明
图1为格氏乳杆菌MY5菌株的系统发育树(菌株来源于NCBI的Genome数据库,其中Lactobacillus gasseri MY4为发明人同一时间段申报的另一个菌株,保藏号为CCTCC NO:M20231159);
图2为格氏乳杆菌MY5菌株对纤维素平板的降解实验(左边,空白对照组;右边,实验组);
图3为格氏乳杆菌MY5菌株可以产生和分泌3-羟基丁酸;
图4为格氏乳杆菌MY5发酵液可分泌物质显著抑制α-葡萄糖苷酶活性;
图5为格氏乳杆菌MY5发酵液可分泌物质显著抑制乙酰胆碱酯酶活性。
具体实施方式
下面对本发明的具体实施方式作进一步说明。在此需要说明的是,对于这些实施方式的说明用于帮助理解本发明,但并不构成对本发明的限定。此外,下面所描述的本发明各个实施方式中所涉及的技术特征只要彼此之间未构成冲突就可以相互组合。
下述实施例中的实验方法,如无特殊说明,均为常规方法,下述实施例中所用的试验材料,如无特殊说明,均为可通过常规的商业途径购买得到。
下列实施例涉及的实验材料如下:
(1)格氏乳杆菌(Lactobacillus gasseri)MY5菌株,分离自中国广东广州地区一名健康成年人(BMI=18.8)的肠道粪便样品中,于甘油管内置于-80℃低温冷冻保藏。一般情况下,将该菌株接种于MRS固体培养基平板表面,并在37℃恒温厌氧培养箱中倒置培养24h可获得菌落,或在37℃恒温厌氧培养箱内于MRS液体培养基中振荡培养24-48h可获得发酵液。
(2)试剂盒:3-羟基丁酸(3-HB)检测试剂盒(Cloud-Clone Corp.,Cat:CEB022Ge),α-葡萄糖苷酶抑制剂筛选试剂盒(abcam,Cat:ab284520),乙酰胆碱酯酶抑制剂筛选试剂盒(abnova,Cat:KA6219)。
(3)MRS平板:牛肉膏10g,蛋白胨10g,酵母膏5g,柠檬酸三铵2g,乙酸钠5g,葡萄糖20g,磷酸氢二钾2g,吐温80 1mL,硫酸镁0.58g,硫酸锰0.25g,琼脂15g,ddH2O补齐至1L,调pH至6.2-6.6,121℃高压灭菌20min,配置成MRS平板。
(4)MRS液体培养基:牛肉膏10g,蛋白胨10g,酵母膏5g,柠檬酸三铵2g,乙酸钠5g,葡萄糖20g,磷酸氢二钾2g,吐温80 1mL,硫酸镁0.58g,硫酸锰0.25g,ddH2O补齐至1L,调pH至6.2-6.6,121℃高压灭菌20min,配置成MRS液体培养基。
(5)CMC平板:羧甲基纤维素钠10g,硫酸铵1.5g,硫酸锰0.3g,氯化钙0.2g,氯化钠5g,尿素0.3g,牛肉膏10g,蛋白胨10g,酵母膏5g,葡萄糖20g,柠檬酸三铵2g,乙酸钠5g,磷酸氢二钾2g,吐温80 0.5mL,硫酸镁0.58g,硫酸锰0.25g,琼脂15g,ddH2O补齐至1L,调pH至6.2-6.6,121℃高压灭菌20min,配置成CMC平板。
实施例1格氏乳杆菌(Lactobacillus gasseri)MY5菌株的分离鉴定
格氏乳杆菌Lactobacillus gasseri MY5菌株从中国广东广州地区一名健康成年人(BMI=18.8)的肠道粪便样品中分离得到,具体如下:
用无菌水将粪便样品反复清洗3次,置于研钵中,每100mg粪便加入500uL无菌水,彻底研磨匀浆,用移液器吸取适量研磨液,涂布于MRS平板上,室温培养3天。然后,用记号笔对分离实验平板中待划线纯化的菌落进行编号,并相应地在平板上标明菌株编号。标记后,挑取菌落接种到MRS平板上,用平板划线法纯化菌株。若此法不能将菌株分离则需要从富集平板上挑取菌落,经MRS液体培养基梯度稀释后,涂布于培养基上。最后,参考《伯杰细菌鉴定手册》(第八版)和《真菌分类鉴定手册》,首先分辨属于细菌的菌株,然后观察菌落的生长状况:生长形态、是否有菌丝、颜色是否均匀一致,菌落个体表面及边缘。初步分离得到一株纯化菌株,培养24小时后观察到菌株的菌落为圆形凸起、光滑、边缘整齐、不透明的乳白色,菌株编号为MY5。
接着,通过16S rDNA通用引物(27F:AGAGTTTGATCCTGGCTCAG,1492R:TACGGCTACCTTGTTACGACTT)对分离得到的MY5菌株进行分子鉴定后,由北京百迈客生物科技有限公司对MY5菌株进行全基因组测序。将得到的序列16S rDNA sequence(SEQ ID No:1)在NCBI的Genome数据库进行BLAST比对。结果显示,与已知的格氏乳杆菌(Lactobacillusgasseri)16S rDNA序列的同源性>99%,并与同源菌株进行进化分析(图1),确认MY5是同种不同株的格氏乳杆菌。
最后,对菌株MY5进行保藏,保藏信息如下:保藏时间:2023年7月3日;保藏单位名称:中国典型培养物保藏中心(CCTCC);保藏号:CCTCC NO:M 20231160;保藏单位地址:中国.武汉.武汉大学;分类命名:Lactobacillus gasseri。
格氏乳杆菌是可用于食品的益生菌菌株,其具有广泛的益生功效,如抗炎、抗衰老和降胆固醇等,但不同来源的菌株其功效不同,说明本发明从人体粪便分离得到的一株新的格氏乳杆菌MY5可以作为益生菌使用,并可能具有新的功效和功能。
Lactobacillus gasseri MY5 16S rDNA sequence(1450bp,SEQ ID No:1):
CTATACTGCAGTCGAGCGAGCTTGCCTAGATGAATTTGGTGCTTGCACCAAATGAAACTAGATACAAGCGAGCGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCAAGAGACTGGGATAACACCTGGAAACAGATGCTAATACCGGATAACAACACTAGACGCATGTCTAGAGTTTAAAAGATGGTTCTGCTATCACTCTTGGATGGACCTGCGGTGCATTAGCTAGTTGGTAAGGTAACGGCTTACCAAGGCAATGATGCATAGCCGAGTTGAGAGACTGATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGCAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAGCTCTGTTGGTAGTGAAGAAAGATAGAGGTAGTAACTGGCCTTTATTTGACGGTAATTACTTAGAAAGTCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGATTTATTGGGCGTAAAGCGAGTGCAGGCGGTTCAATAAGTCTGATGTGAAAGCCTTCGGCTCAACCGGAGAATTGCATCAGAAACTGTTGAACTTGAGTGCAGAAGAGGAGAGTGGAACTCCATGTGTAGCGGTGGAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTCTCTGGTCTGCAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGATGAGTGCTAAGTGTTGGGAGGTTTCCGCCTCTCAGTGCTGCAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCCAGTGCAAACCTAAGAGATTAGGTGTTCCCTTCGGGGACGCTGAGACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCATTAGTTGCCATCATTAAGTTGGGCACTCTAATGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAGTCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGACGGTACAACGAGAAGCGAACCTGCGAAGGTAAGCGGATCTCTGAAAGCCGTTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACACGAAGCTGGAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGTCTGTAACACCCAAAGCCGGTGGGATAACCTTTATAGGAGTCAGCCGTCTAA。
实施例2格氏乳杆菌(Lactobacillus gasseri)MY5菌株的功能及其应用
(1)格氏乳杆菌MY5菌株可产纤维素酶
使用纤维素板培养基(MP平板)根据琼脂孔扩散法测定格氏乳杆菌MY5对纤维素的降解能力。试验时,往实验组的MP平板中滴加3uL浓度为10Abs的格氏乳杆菌MY5菌液,对照组则滴加3uL空白MRS培养基。并在37℃恒温厌氧培养箱中倒置培养3天后进行刚果红染色。结果表明,与滴加空白培养基的对照相比,菌株MY5可以显著的降解纤维素,形成明显的降解圈(图2)。
由于格氏乳杆菌MY5可产纤维素酶,因此益生菌格氏乳杆菌MY5菌株可通过产生纤维素酶的功效发挥以下多个用途:(1)用于促进对膳食成分的消化吸收;(2)改善便秘,益生菌在肠道内分解纤维素产生一定的水分,具有软化大便的作用;(3)降低胆固醇是纤维素最重要的功效,因为可溶性纤维在被人体吸收后,能抑制人体对胆固醇的吸收,并能在肠道中与胆固醇结合,加快身体内胆固醇的代谢,防止人体因胆固醇过高而诱发高血脂,并且能降低动脉硬化与冠心病的发病率;(4)纤维素这种不甜的“糖”能够减缓血液对葡萄糖的吸收,平衡血糖浓度,促进肌肉和脂肪细胞对胰岛素的敏感性,从而预防并辅助治疗糖尿病。
此外,格氏乳杆菌MY5还可以应用于纤维素酶的发酵提取;应用于降解病原真菌的细胞壁,控制病害;应用于堆肥中纤维素的分解;应用于制备畜禽养殖饲料,如猪、鸡等单胃动物饲料,以克服其不能利用纤维素的缺陷。
(2)格氏乳杆菌MY5菌株可产生和分泌3-羟基丁酸(3-HB)
将用MRS液体培养基培养至稳定期的格氏乳杆菌MY5以1:30的稀释倍数扩培至新的MRS液体培养基中,在培养至稳定期24h时收取菌悬液,10,000×g、4℃离心10min后收取发酵液上清,然后通过3-HB特定ELISA试剂盒(CEB022Ge)测定发酵液上清的3-HB浓度。结果显示,与空白培养基MRS中不存在3-HB相比,菌株MY5的上清液中3-HB的浓度为0.48μg/mL,说明格氏乳杆菌MY5可以在稳定期产生并分泌3-羟基丁酸(图3)。
3-HB为可以身体各种活动提供能量,是潜在的能量/功能型食物,已被添加到运动员饮料中,因此益生菌格氏乳杆菌MY5可作为能量型食品的添加剂。同时,鉴于3-HB可以有效的抗骨质疏松,预防及治疗慢性综合征(高血压,酒精性脂肪肝,肠炎,肠癌),改善脑部认知功能(提高学习记忆的能力,保护神经胶质细胞,改善阿尔兹海默症),改善脂代谢。益生菌格氏乳杆菌MY5菌株可通过产生3-羟基丁酸的功效发挥以上多个用途。
此外,3-羟基丁酸是是机体天然产生的一种内源性小分子物质,对维持结肠直肠组织完整性具有重要作用,并且具有维持肠道健康、防止结肠疾病和消炎产能的作用。通过3-HB处理可以促进肠道有益菌增殖,缓解多发性硬化的症状,在调节菌群改善健康方面具有巨大的潜力。因此,益生菌格氏乳杆菌MY5菌株也有助于改善肠道菌群,缓解肠道炎症。
(3)格氏乳杆菌MY5菌株发酵液可有效抑制α-葡萄糖苷酶活性
将用MRS液体培养基培养至稳定期的格氏乳杆菌MY5以1:30的稀释倍数扩培至新的MRS液体培养基中,在培养至稳定期24h时收取菌悬液,10,000×g、4℃离心10min后收取发酵液上清,然后通过α-葡萄糖苷酶抑制剂筛选试剂盒(ab284520)测定发酵液上清对α-葡萄糖苷酶水解葡萄糖的酶活性能力的影响。结果显示,与空白培养基MRS的无抑制作用相比,菌株MY5的发酵上清液显著抑制了α-葡萄糖苷酶水解葡萄糖的能力,其抑制率约为14.78%,说明格氏乳杆菌MY5的发酵液可以有效的抑制α-葡萄糖苷酶的活性(图4)。
a-葡萄糖苷酶是一种在碳水化合物分解中起作用的酶,与2型糖尿病有关,抑制α-葡萄糖苷酶是控制餐后高血糖的方法之一,从而有助于糖尿病的治疗。因此,α-葡萄糖苷酶抑制剂有助于维持血糖平,能够改善糖尿病并发症。此外,抑制α-葡萄糖苷酶的活性可以控制肥胖。
因此,益生菌格氏乳杆菌MY5菌株具有抑制a-葡萄糖苷酶活性,这使它成为潜在的降血糖和抑制肥胖的益生菌。
(4)格氏乳杆菌MY5菌株发酵液可有效抑制乙酰胆碱酯酶活性
将用MRS液体培养基培养至稳定期的格氏乳杆菌MY5以1:30的稀释倍数扩培至新的MRS液体培养基中,在培养至稳定期24h时收取菌悬液,10,000×g、4℃离心10min后收取发酵液上清,然后通过乙酰胆碱酯酶抑制剂筛选试剂盒(KA6219)测定发酵液上清对乙酰胆碱酯酶(AchE)活性的抑制能力。结果显示,与空白培养基MRS的无抑制作用相比,菌株MY5的发酵上清液显著抑制了乙酰胆碱酯酶的活性,其抑制率约为27.09%,说明格氏乳杆菌MY5的发酵液可以有效的抑制乙酰胆碱酯酶的活性(图4)。
乙酰胆碱酯酶抑制剂通过对乙酰胆碱酯酶的可逆性抑制,让胆碱够在神经纤维末梢释放的乙酰胆碱的作用下不断堆积于突触处,兴奋胆碱受体,延长并且增加了乙酰胆碱的作用。乙酰胆碱酯酶抑制剂可增强认知能力和记忆力(改善阿尔茨海默症、改善认知障碍),扩张血管(改善心率过速),兴奋骨骼肌和平滑肌(改善便秘、术后腹胀、术后尿潴留)。
因此,益生菌格氏乳杆菌MY5菌株可抑制乙酰胆碱酯酶活性,可以兴奋骨骼肌和肠道的平滑肌,这使它成为潜在的促进胃肠道吸收和蠕动的益生菌。
综上可知,本发明新分离的格氏乳杆菌(Lactobacillus gasseri)MY5菌株具有的多种益生功效:(1)具有优越的纤维素酶活性;(2)可产生和分泌3-羟基丁酸;(3)可抑制α-葡萄糖苷酶活性;(4)可抑制乙酰胆碱酯酶活性。可见,本发明新分离得到的格氏乳杆菌MY5菌株具有重要的应用价值和经济价值。
以上对本发明的实施方式作了详细说明,但本发明不限于所描述的实施方式。对于本领域的技术人员而言,在不脱离本发明原理和精神的情况下,对这些实施方式进行多种变化、修改、替换和变型,仍落入本发明的保护范围内。
Claims (8)
1.一株格氏乳杆菌(Lactobacillus gasseri)MY5菌株,其特征在于,所述格氏乳杆菌MY5菌株于2023年7月3日保藏于中国典型培养物保藏中心,保藏号为:CCTCC NO:M20231160;所述格氏乳杆菌MY5菌株的16S rDNA全序列如SEQ ID No:1所示。
2.权利要求1所述的格氏乳杆菌(Lactobacillus gasseri)MY5菌株在产纤维素酶中的应用。
3.权利要求1所述的格氏乳杆菌(Lactobacillus gasseri)MY5菌株在产3-羟基丁酸中的应用。
4.权利要求1所述的格氏乳杆菌(Lactobacillus gasseri)MY5菌株在制备α-葡萄糖苷酶抑制剂中的应用。
5.权利要求1所述的格氏乳杆菌(Lactobacillus gasseri)MY5菌株在制备乙酰胆碱酯酶抑制剂中的应用。
6.一种具有益生功能的菌剂,其特征在于,所述菌剂包括权利要求1所述的格氏乳杆菌(Lactobacillus gasseri)MY5菌株。
7.根据权利要求6所述的一种具有益生功能的菌剂,其特征在于,所述菌剂为权利要求1所述的格氏乳杆菌(Lactobacillus gasseri)MY5菌株经发酵后的产物。
8.根据权利要求6所述的一种具有益生功能的菌剂,其特征在于,在医药应用领域,所述菌剂还包括药学上可接受的辅料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311316085.XA CN117343875A (zh) | 2023-10-12 | 2023-10-12 | 一株格氏乳杆菌my5及其在制备抗炎和通便护肠食品药品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311316085.XA CN117343875A (zh) | 2023-10-12 | 2023-10-12 | 一株格氏乳杆菌my5及其在制备抗炎和通便护肠食品药品中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117343875A true CN117343875A (zh) | 2024-01-05 |
Family
ID=89360755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311316085.XA Pending CN117343875A (zh) | 2023-10-12 | 2023-10-12 | 一株格氏乳杆菌my5及其在制备抗炎和通便护肠食品药品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117343875A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116083307A (zh) * | 2023-01-10 | 2023-05-09 | 四川轻化工大学 | 一种生产酯酶和酯类化合物的格氏乳球菌及其应用 |
-
2023
- 2023-10-12 CN CN202311316085.XA patent/CN117343875A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116083307A (zh) * | 2023-01-10 | 2023-05-09 | 四川轻化工大学 | 一种生产酯酶和酯类化合物的格氏乳球菌及其应用 |
CN116083307B (zh) * | 2023-01-10 | 2024-05-07 | 四川轻化工大学 | 一种生产酯酶和酯类化合物的格氏乳球菌及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116555076B (zh) | 一株长双歧杆菌长亚种my1及其在制备通便和护肠食品药品中的应用 | |
CN116814464B (zh) | 一株发酵粘液乳杆菌jf5及其在制备减脂和助消化食品药品中的应用 | |
CN116083325B (zh) | 一种改善幽门螺杆菌相关性胃肠疾病的鼠李糖乳杆菌及其应用 | |
CN117343875A (zh) | 一株格氏乳杆菌my5及其在制备抗炎和通便护肠食品药品中的应用 | |
CN116555075B (zh) | 一株植物乳植杆菌jf1及其在制备抗衰老食品药品中的应用 | |
CN116555074B (zh) | 一株短乳杆菌jt1及其在制备降血糖药品中的应用 | |
CN116218733B (zh) | 一株鼠李糖乳酪杆菌xy5及其在制备抗过敏和助消化食品药品中的应用 | |
CN116656526B (zh) | 一株植物乳植杆菌jf4及其在制备降血糖和降胆固醇食品药品中的应用 | |
CN116286519B (zh) | 一株副干酪乳酪杆菌ks3及其在制备抗衰老和助消化食品药品中的应用 | |
CN117004503B (zh) | 一株唾液联合乳杆菌mb1及其在制备助睡眠和调理肠胃食品药品中的应用 | |
CN117363524B (zh) | 一株格氏乳杆菌my4及其在制备助睡眠和美白药品中的应用 | |
CN116574634B (zh) | 一株唾液链球菌嗜热亚种jf2及其在制备抗炎和解脂食品药品中的应用 | |
CN117384790B (zh) | 一株戊糖片球菌ks5及其在制备助睡眠药品中的应用 | |
CN117286045B (zh) | 一株长双歧杆菌长亚种ks2及其在制备抗衰老药品中的应用 | |
CN115992059B (zh) | 一株产阿魏酸酯酶的约氏乳杆菌及其缓解溃疡性结肠炎的用途 | |
CN116496938B (zh) | 一株产透明质酸的嗜酸乳杆菌my2及其在制备抗衰老和美白食品药品中的应用 | |
CN117683663A (zh) | 一株桥粘液乳杆菌jt3及其在制备降糖和降尿酸食品药品中的应用 | |
CN117431179A (zh) | 一株格氏乳杆菌my4及其在制备调理肠胃和降尿酸食品药品中的应用 | |
CN117402768B (zh) | 一株罗伊氏粘液乳杆菌ka1及其在制备抗炎抗肿瘤药品中的应用 | |
CN117866841A (zh) | 一株粪肠球菌xy2及其在制备调理肠胃和改善痛风食品药品中的应用 | |
CN117946937A (zh) | 一株植物乳植杆菌xy1及其在制备降血糖和改善痛风食品药品中的应用 | |
CN117946936A (zh) | 一株植物乳植杆菌xy4及其在制备助消化和抗炎食品药品中的应用 | |
CN118028148A (zh) | 一株粪肠球菌mb2及其在制备抗炎和降血糖食品药品中的应用 | |
CN117946941A (zh) | 一株植物乳植杆菌my6及其在制备抗炎和通便护肠食品药品中的应用 | |
CN118109345A (zh) | 一株粪肠球菌xy3及其在制备抗炎和助睡眠食品药品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |